Das Speicherverhalten von ⁶⁷Ga bei Erkrankungen der großen Kopfspeicheldrüsen

ln a prospective study (59 patients) the pattern of ⁶⁷Ga-uptake of the large salivary glands (LSG) in the course of typical disorders of the glands was investigated. Inflammatory and granulomatous disorders revealed - dependent on their acuity - an identical pattern of Ga-uptake. Extraglandular uptake was found in some instances of tuberculosis, sarcoidosis and myoepithelial sialadenitis. Among the benign LSG tumors all cystadeno- lymphomas showed intensive uptake while all pleomorphic adenomas did not. In 75% of the malignant LSG tumors Ga-uptake was pathologically increased, particularly in all adenocarcinomas of the series. ⁶⁷Ga scintigraphy seems to be useful in the follow-up of inflammatory and granulomatous LSG disorders and in the differential diagnosis of pleomorphic adenoma versus cystadenolymphoma. Extraglandular uptake may give valuable hints for diagnostic work-up.

Zusammenfassung

Das ⁶⁷Ga-Speicherverhalten der häufigsten Erkrankungen der großen Kopfspeicheldrüsen (GSD) wurde in einer prospektiven Studie (59 Patienten) untersucht. Es zeigte sich bei den entzündlichen und granulomatösen Speicheldrüsenerkrankungen - abhängig von ihrer Akuizitätein identisches Ga-Speichermuster. Zusätzliche extraglanduläre Mehrspeicherungen fanden sich bei einigen granulomatösen und myoepithelialen Sialadeniti- den. Bei den benignen Tumoren der GSD zeigten alle Zystadenolymphome eine erhöhte Ga-Speicherung, während sämtliche pleomorphen Adenome keine erhöhte Ga-Aufnahme aufwiesen. Bei 75% der malignen Speicheldrüsentumoren war die Ga-Speicherung erhöht, die Subpopulation der untersuchten Adenokarzinome war in jedem Falle galliumpositiv. Die ⁶⁷Ga-Szintigraphie erscheint somit nützlich in der Verlaufskontrolle von entzündlichen und granulomatösen Erkrankungen der GSD und bei der Differentialdiagnose pleomorphes Adenom versus Zystadenolymphom. Eine extraglanduläre Ga-Speicherung kann diagnostisch richtungsweisend sein.

• LITERATUR

• R1 Andrew G. A, Hubner K. F, Greenlaw R. H. Gallium-67-citrate imaging in malignant lymphome. Final report of cooperative group. J. nucl. Med 1978; 19: 1013-9.
• R2 Bekerman C, Hoffer P. B, Bitran J. D. The role of gallium-67 in the clinical evaluation of cancer. Semin, nucl. Med 1985; 15: 72-103.
• R3 Bekerman C, Hoffer P. B. Salivary gland uptake of ⁶⁷Gacitrate following radiation therapy. J. nucl. Med 1976; 17: 685-7.
• R4 Bihl H, Maier H. Unilateral gallium-67 uptake in primary tuberculosis of the major salivary glands (accepted for publication in Clin nucl. Med. 1987)
• R5 Bihl H, Kimmig B. Falsch positive Befunde der Gallium-67-Szintigraphie beim Staging/Restaging von malignen Lymphomen. Fortschr. Röntgenstr 1987; 146: 172-7.
• R6 Caselitz J, Jamp T, Seifert G. Lactoferrin and lysozymes in carcinomas of the parotid gland. A comparative immunocytochemical study with the occurrance in normal and inflamed tissue. Virchows Arch. path. Anat 1981; 394: 61.
• R7 Collius R. D, Ball G. V, Logic J. R. Gallium-67 scanning in Sjogren’s syndrome. J. nucl. Med 1984; 25: 299-302.
• R8 Garcia R. R. Differential diagnosis of tumors of the salivary glands with radioactive isotopes. Int. J. oral Surg 1974; 3: 330-4.
• R9 Hayes R. L, Carlton J. E. A study of the macromolecular binding of ⁶⁷Ga in normal and malignant animal tissues. Cancer Res 1973; 33: 3265-72.
• R10 Henkin R. E. Gallium-67 in the diagnosis of inflammatory disease. In: Gallium-67 Imaging.. 1978. Hoffer P. B, Bekerman C, Henking R. E. eds.) 65 John Wiley & Sons; New York:
• R11 Heshiki A, Schatz S. L, McKusick K. A. et al. Gallium-67 citrate scanning in patients with pulmonary sarcoidosis. Amer. J. Roentgenol 1974; 122: 744-9.
• R12 Hoffer P. B. Use of gallium-67 for detection of inflammatory disease. A brief review of mechanism and clinical applications. Int. J. nucl. Med. Biol 1981; 8: 243.
• R13 Hoffer P. B, Huberty J, Khayam- Bashi J. The association of Ga-67 and lactoferrin. J. nucl. Med 1977; 18: 713-7.
• R14 Johnston G. S. Clinical application of gallium in oncology. Int. J. nucl. Med. Biol 1981; 8: 249-55.
• R15 Johnston G. S, Go M. S, Benua R. S. et al. Gallium-67-citräte imaging in Hodgkin’s disease. Final report of cooperative group. J. nucl. Med 1977; 18: 692-8.
• R16 Lentle B. C, Jackson F. I, McGowan D. G. Localization of gallium-67 citrate in salivary glands following radiation therapy. J. Canad. Assoc. Radiol 1976; 27: 89-91.
• R17 MacMahon H, Bekerman C. The diagnostic significance of gallium lung uptake in patients with normal chest radiographs. Radiology 1978; 127: 189-93.
• R18 Merz T, Malmud L, McKusick K. et al. The mechanism of ⁶⁷Ga association with lymphocytes. Cancer Res 1974; 34: 2495-9.
• R19 Rubin P, Casarett W. G. Clinical Radiation Pathology. 1968. Chap. 7 W. B. Saunders; Philadelphia:
• R20 Sarkar S. D, Ravikrishnan K. P, Woodbury D. H, Carson J. J, Daley K. Gallium-67 citrate scanning - A new adjunct in the detection and follow-up of extrapulmonary tuberculosis. J. nucl. Med 1979; 20: 833-6.
• R21 Schmid U, Helbron D, Lennert K. Development of malignant lymphoma in myoepithelial sialadenitis (Sjögren-syndrome). Virchows Arch. path. Anat 1982; 395: 11.
• R22 Schwarzendruber D. C, Nelson B, Hayes R. L. ⁶⁷Ga localization in lysosomallike granules of leukemic and nonleukemic murine tissues. J. natl. Cancer Inst 1971; 46: 941-52.
• R23 Siddiqui A. R, Weisberger E. C. Possible explanation of appearance of Warthin’s tumor on 1-123 and Tc-99m- pertechnetate scans. Clin. nucl. Med 1981; 6: 258-60.
• R24 Siemsen J. K, Grebe S. F, Sargent E. N. et al. Gallium-67 scintigraphy of pulmonary diseases as a complement to radiography. Radiology 1976; 118: 371-5.
• R25 Strimlan C. V, Resenow E. C, Divertie M. B. et al. Pulmonary manifestations of Sjogren’s Syndrome. Chest 1976; 70: 354-61.
• R26 Thadepalli H, Rhambhata K, Mishkin F. S. et al. Correlation of microbiologic findings and ⁶⁷gallium scans in patients with pulmonary infections. Chest 1977; 72: 442-8.
• R27 Wiener S. L, Patel B. P. ⁶⁷Gacitrate uptake by the parotid glands in sarcoidosis. Radiology 1979; 130: 753-5.